ArticlePloS one2026
Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the 6-week mortality of acute gastrointestinal bleeding in patients with liver cirrhosis and portal vein thrombosis and to analyze its influencing factors.
methodsThis was a retrospective study. We retrospectively screened 232 patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding who were admitted to West China Hospital of Sichuan University from January 1，2020 to November30，2022. Of the 232 patients, 75 had their first bleeding. Additionally, the patients were divided into a mortality group (n = 34) and a non-mortality group (n = 198) based on whether they died within 6 weeks of the onset of gastrointestinal bleeding. Baseline general information, laboratory indicators, and other clinical data of the two groups were compared, and the independent risk factors for 6-week mortality in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding were analyzed.
resultsThere were significant differences between the two groups in terms of the etiology of liver cirrhosis, HCC, 5-day treatment failure rate (8.62%), TBiL, ALT, BUN, Na, eGFR, DBiL, AST, GGT, ALP, CR, WBC, PLT, and PT(p < 0.05). Multivariate logistic regression analysis revealed that elevated ALP levels showed a positive association with 6-week mortality [OR=1.01, 95% CI (1.01, 1.01), p < 0.01] and 5-day treatment failure showed a positive association with 6-week mortality [OR=11.27, 95% CI (3.45, 36.81),p < 0.01].
conclusionElevated ALP and 5-day treatment failure were found to be independent risk factors for 6-week mortality in patients with cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.